Exploring Azole Antifungal Drug Resistance in Aspergillus fumigatus with Special Reference to Resistance Mechanisms
- 1 May 2014
- journal article
- review article
- Published by Informa UK Limited in Future Microbiology
- Vol. 9 (5), 697-711
- https://doi.org/10.2217/fmb.14.27
Abstract
Aspergillus fumigatus, a ubiquitously distributed opportunistic pathogen, is the global leading cause of aspergillosis. Azole antifungals play an important role in the management of aspergillosis. However, over a decade, azole resistance in A. fumigatus isolates has been increasingly reported with variable prevalence worldwide and it is challenging the effective management of aspergillosis. The high mortality rates observed in patients with invasive aspergillosis caused by azole-resistant A. fumigatus (ARAF) isolates pose serious challenges to the clinical microbiologist for timely identification of resistance and appropriate therapeutic interventions. The majority of ARAF isolates contain alterations in the cyp51A gene; however, there have been increasing reports on non-cyp51A mutations contributing to azole resistant phenotypes. This review highlights the emergence and various mechanisms implicated in the development of azole resistance in A. fumigatus. We further present recent developments related to the environmental route in the emergence of ARAF isolates and discuss the therapeutic options available.Keywords
Funding Information
- Commission Research fellowship (F.2-15/2003 SA-I)
- Astellas
- Basilea
- Merck
This publication has 100 references indexed in Scilit:
- Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatusMolecular Ecology, 2011
- Interrogation of Related Clinical Pan-Azole-Resistant Aspergillus fumigatus Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms in cyp51A , Upregulation of cyp51A , and Integration and Activation of Transposon Atf1 in the cyp51A PromoterAntimicrobial Agents and Chemotherapy, 2011
- Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A GeneAntimicrobial Agents and Chemotherapy, 2011
- Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to PosaconazoleAntimicrobial Agents and Chemotherapy, 2011
- Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump ActivityAntimicrobial Agents and Chemotherapy, 2011
- High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal DiseaseClinical Infectious Diseases, 2011
- Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and SpainAntimicrobial Agents and Chemotherapy, 2010
- Expression, Purification, and Characterization of Aspergillus fumigatus Sterol 14-α Demethylase (CYP51) Isoenzymes A and BAntimicrobial Agents and Chemotherapy, 2010
- Aspergillus fumigatusmetabolism: Clues to mechanisms ofin vivofungal growth and virulenceMedical Mycology, 2009
- Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2008